756893-89-7

Upstream product

• 756893-85-3 (1R,5R)-5-(tert-Butyl-dimethyl-silanyloxy)-1-hydroxy-4-methyl-cyclohex-3-enecarboxylic acid 
• 766529-94-6 (1R,3R,5R)-3-[(tert-butyldimethylsilyl)oxy]-1-hydroxy-6-oxa-bicyclo[3.2.1]octane-4,7-dione 
• 852380-46-2 (1R,3R,5R)-3-(tert-Butyl-dimethyl-silanyloxy)-1-hydroxy-4-methylene-6-oxa-bicyclo[3.2.1]octan-7-one 
• 756893-86-4 (1R,5R)-5-(tert-Butyl-dimethyl-silanyloxy)-1-hydroxy-4-methyl-cyclohex-3-enecarboxylic acid methoxy-methyl-amide 
• 756893-81-9 [5-(tert-butyl-dimethyl-silanyloxy)-1-hydroxy-4-methyl-cyclohex-3-enyl]-[1-(2-trimethylsilanyl-ethoxymethyl)-1H-pyrrol-2-yl]-methanone 
• 756894-00-5 (1R,8R,10R,11R)-10-(tert-Butyl-dimethyl-silanyloxy)-8-hydroxy-11-methyl-5-(2-trimethylsilanyl-ethoxymethyl)-5-aza-tricyclo[6.3.1.0^2,6]dodeca-2⁽⁶⁾,3-dien-7-one 
• 756893-87-5 (1R,8R,10R,11R)-10-(tert-Butyl-dimethyl-silanyloxy)-8-methoxy-11-methyl-5-(2-trimethylsilanyl-ethoxymethyl)-5-aza-tricyclo[6.3.1.0^2,6]dodeca-2⁽⁶⁾,3-dien-7-one 
• 756893-98-8 [3-bromo-1-(2-trimethylsilanyl-ethoxymethyl)-1H-pyrrol-2-yl]-[5-(tert-butyl-dimethyl-silanyloxy)-1-hydroxy-4-methyl-cyclohex-3-enyl]-methanone 
• 756893-79-5 (1S,8R,10R)-10-(tert-Butyl-dimethyl-silanyloxy)-8-hydroxy-11-methylene-5-(2-trimethylsilanyl-ethoxymethyl)-5-aza-tricyclo[6.3.1.0^2,6]dodeca-2⁽⁶⁾,3-dien-7-one 
• 756894-01-6 (1R,8R,10R,11R)-3-Bromo-10-(tert-butyl-dimethyl-silanyloxy)-8-methoxy-11-methyl-5-(2-trimethylsilanyl-ethoxymethyl)-5-aza-tricyclo[6.3.1.0^2,6]dodeca-2⁽⁶⁾,3-dien-7-one 
• 756893-77-3 (1R,8R,10R,11R)-10-(tert-Butyl-dimethyl-silanyloxy)-8-methoxy-11-methyl-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5-aza-tricyclo[6.3.1.0^2,6]dodeca-2⁽⁶⁾,3-dien-7-one 
• 756893-88-6 (1R,8R,10R,11R)-3-{5-[6-Bromo-1-(toluene-4-sulfonyl)-1H-indol-3-yl]-6-methoxy-pyrazin-2-yl}-10-(tert-butyl-dimethyl-silanyloxy)-8-methoxy-11-methyl-5-(2-trimethylsilanyl-ethoxymethyl)-5-aza-tricyclo[6.3.1.0^2,6]dodeca-2⁽⁶⁾,3-dien-7-one 
• 76513-69-4 (2-trimethylethylsilylethoxy)methyl chloride 
• 756893-97-7 2,3-dibromo-1-(2-trimethylsilanyl-ethoxymethyl)-1H-pyrrole 

Downstream Products

• 756894-03-8 (1R,8R,11R)-3-{5-[6-Bromo-1-(toluene-4-sulfonyl)-1H-indol-3-yl]-6-methoxy-pyrazin-2-yl}-8-methoxy-11-methyl-5-(2-trimethylsilanyl-ethoxymethyl)-5-aza-tricyclo[6.3.1.0^2,6]dodeca-2⁽⁶⁾,3-diene-7,10-dione 10-oxime 
• 852380-49-5 (1R,8S,9R,11R)-9-Bromo-3-{5-[6-bromo-1-(toluene-4-sulfonyl)-1H-indol-3-yl]-6-methoxy-pyrazin-2-yl}-8-methoxy-11-methyl-5-(2-trimethylsilanyl-ethoxymethyl)-5-aza-tricyclo[6.3.1.0^2,6]dodeca-2⁽⁶⁾,3-diene-7,10-dione 
• 756893-90-0 C₄₆H₅₀BrN₅O₉S₂Si 

Relevant academic research and scientific papers

Development of an enantiodivergent strategy for the total synthesis of (+)- and (-)-dragmacidin f from a single enantiomer of quinic acid

An enantiodivergent strategy for the total chemical synthesis of both (+)- and (-)-dragmacidin F beginning from a single enantiomer of quinic acid has been developed and successfully implemented. Although unique, the synthetic routes to these antipodes share a number of key features, including novel reductive isomerization reactions, Pd(II)-mediated oxidative carbocyclization reactions, halogen-selective Suzuki couplings, and high-yielding late-stage Neber rearrangements.

The total synthesis of (+)-dragmacidin F

The first total synthesis of (+)-dragmacidin F has been accomplished, establishing the absolute configuration of this biologically important, antiviral marine alkaloid. The convergent route described features a palladium-mediated oxidative pyrrole carbocy